Financial reports
10-Q
2024 Q3
Quarterly report
12 Nov 24
10-Q
2024 Q2
Quarterly report
6 Aug 24
10-Q
2024 Q1
Quarterly report
9 May 24
ARS
2023 FY
Annual report to shareholders
19 Apr 24
10-K
2023 FY
Annual report
13 Mar 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
17 Apr 23
10-K
2022 FY
Annual report
22 Feb 23
Current reports
8-K
Other Events
6 Feb 25
8-K
Termination of a Material Definitive Agreement
30 Dec 24
8-K
Regulation FD Disclosure
9 Dec 24
8-K
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
12 Nov 24
8-K
Regulation FD Disclosure
4 Oct 24
8-K
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
6 Aug 24
8-K
Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results from Phase 3 Trial of Hemophilia a Gene Therapy Candidate
24 Jul 24
8-K
Departure of Directors or Certain Officers
5 Jun 24
8-K
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
9 May 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Apr 24
Registration and prospectus
S-8
Registration of securities for employees
12 Nov 24
S-3
Shelf registration
12 Nov 24
424B5
Prospectus supplement for primary offering
25 Mar 24
S-8
Registration of securities for employees
8 Aug 23
424B5
Prospectus supplement for primary offering
7 Mar 23
S-8
Registration of securities for employees
23 Feb 23
POS AM
Prospectus update (post-effective amendment)
23 Feb 23
POSASR
Automatic shelf registration (post-effective amendment)
22 Feb 23
424B5
Prospectus supplement for primary offering
23 Dec 22
S-3ASR
Automatic shelf registration
5 May 21
Proxies
DEF 14A
Definitive proxy
19 Apr 24
PRE 14A
Preliminary proxy
3 Apr 24
DEF 14A
Definitive proxy
17 Apr 23
PRE 14A
Preliminary proxy
5 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
1 Apr 22
DEF 14A
Definitive proxy
2 Apr 21
DEFA14A
Additional proxy soliciting materials
8 May 20
DEF 14A
Definitive proxy
2 Apr 20
PRE 14A
Preliminary proxy
23 Mar 20
Other
EFFECT
Notice of effectiveness
20 Nov 24
EFFECT
Notice of effectiveness
24 Apr 23
CT ORDER
Confidential treatment order
3 Feb 20
CT ORDER
Confidential treatment order
26 Feb 19
CT ORDER
Confidential treatment order
26 Feb 19
CT ORDER
Confidential treatment order
26 Feb 19
CT ORDER
Confidential treatment order
3 Dec 18
CT ORDER
Confidential treatment order
25 Jun 18
CT ORDER
Confidential treatment order
26 Apr 18
CT ORDER
Confidential treatment order
12 Sep 17
Ownership
4
Gregory D Davis
26 Feb 25
4
Nathalie Dubois-Stringfellow
26 Feb 25
4
Scott B. Willoughby
26 Feb 25
4
Prathyusha Duraibabu
26 Feb 25
4
Sandy Macrae
26 Feb 25
4
Gregory D Davis
24 Jan 25
4
Nathalie Dubois-Stringfellow
24 Jan 25
4
Scott B. Willoughby
24 Jan 25
4
Prathyusha Duraibabu
24 Jan 25
4
Sandy Macrae
24 Jan 25